Insider Shareholders with Direct Ownership of An2 Therapeutics, Inc. (ANTX)
ANTX Quotes by TradingView
This section provides a comprehensive overview of the insiders with direct ownership of An2 Therapeutics, Inc. (ANTX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
AN2 Therapeutics, Inc. Insider List
Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
---|---|---|---|---|---|
Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
0 | 214,777 | 2,184,224 $2.66 Million | 11 |
Jun 06, 2022
Reduced 1.2%
|
|
Eric Easom
Chief Executive Officer |
249,157 | 97,008 | 246,380 $300,583 | 20 |
Feb 26, 2025
Added 37.09%
|
180,000 | 9,663 | 175,172 $213,709 | 5 |
Feb 26, 2025
Added 25.04%
|
|
145,538 | 0 | 145,538 $177,556 | 6 |
Apr 10, 2025
Added 6.74%
|
|
Sanjay Chanda
Chief Development Officer |
77,750 | 2,957 | 80,074 $97,690 | 3 |
Feb 26, 2025
Added 38.56%
|
Lucy Day
Chief Financial Officer |
74,000 | 2,957 | 79,170 $96,587 | 3 |
Feb 26, 2025
Added 37.0%
|
Stephen David Prior
Chief Strategy Officer |
38,125 | 2,029 | 61,313 $74,801 | 3 |
Feb 26, 2025
Added 31.35%
|
Paul Eckburg
Chief Medical Officer |
30,000 | 0 | 51,416 $62,727 | 1 |
Mar 15, 2024
Added 36.85%
|
18,677 | 0 | 41,507 $50,638 | 2 |
Apr 10, 2025
Added 18.95%
|
|
Kevin Michael Krause
Chief Strategy Officer |
40,000 | 10,000 | 31,914 $38,935 | 5 |
Mar 15, 2024
Added 48.45%
|
18,677 | 0 | 18,677 $22,785 | 2 |
Apr 10, 2025
Added 34.19%
|
|
9,077 | 0 | 9,077 $11,073 | 1 |
Dec 19, 2024
Added 50.0%
|
|
6,231 | 0 | 6,231 $7,601 | 2 |
Apr 10, 2025
Added 32.97%
|
Showing 1 to 13 of 13 entries